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ABSTRACT: Direct polymer conjugation at peptide tyrosine residues is described. In this study Tyr residues of both Leucine 
enkephalin and salmon calcitonin (sCT) were targeted using appropriate diazonium salt terminated linear mPEGs and poly(mPEG) 
methacrylate prepared by ATRP. Judicious choice of the reaction conditions – pH, stoichiometry and chemical structure of diazoni-
um salt – led to high degree of site-specificity in the conjugation reaction even in the presence of competitive peptide aminoacid 
targets such as histidine, lysines and N-terminal amine. In vitro studies showed that conjugation of mPEG2000 to sCT did not affect 
the peptide ability to increase of intracellular cAMP induced in T47D human breast cancer cells bearing sCT receptors. Preliminary 
in vivo investigation showed preserved ability to reduce [Ca2+] plasma levels by mPEG2000-sCT conjugate in rat animal models. 
Conjugation of poly(ethylene glycol), PEGylation, of bio-
logically relevant peptide and protein drugs is a strategy that 
prolongs therapeutic half-life and reduces immunogenicity.1-4 
A number of PEG-protein therapeutics are currently pre-
scribed for the treatment of a range of prevalent conditions 
including Hepatitis C, chemotherapy-associated neutropenia 
and leukemia and many more are currently in clinical and pre-
clinical development.2 PEGylation generally occurs by target-
ing nucleophilic aminoacids, such as the primary amine at N-
termini, hystidine, lysine and at thiols at free cysteine residues 
with end-functional PEGs.5, 6 In order for PEGylated proteins 
and peptides to retain an acceptable proportion of their origi-
nal activity, conjugation must not occur at, or at the immediate 
vicinity of, crucial points in the polypeptide sequence. These 
would include at the binding sites of hormones or at the cata-
lytic sites of enzymes. It is therefore key that polymer conju-
gation occurs preferentially, when not exclusively, at specific 
aminoacids known for not being part of (poly)peptide active 
sites. PEGylated protein therapeutics consisting of a mixture 
of positional isomers (PEGamers) – i.e. PEGylated IFN alfa-
2a and 2b currently prescribed as first line treatment for hepa-
titis C and some forms of melanoma –have received in the past 
regulatory approval. This is due to largely improved pharma-
cokinetic profile and clinical efficacy compared to the native 
protein therapeutics. However, upon polymer conjugation-
some of these therapeutics retain only a fraction of the activity 
of the original protein (as low as 7% for PEGylated IFN-alfa-
2a).  Although in vitro activity is only one of the many com-
ponent responsible for the overall therapeutic efficacy of these 
biohybrid materials,the development of site specific conjuga-
tion strategies which are able to circumvent this problem is 
now considered a priority in PEGylation and conjugation sci-
ence.  To this end, in recent years considerable research effort 
has been spent in identifying and developing alternative and 
complementary PEGylation strategies to those being clinically 
used. One breakthrough was the work by Brocchini and 
coworkers, who first described the site-specific PEGylation of 
disulfide bridges of a number of protein and peptides using 
novel --unsaturated sulfone derivatives.7, 8 
The growing demand for the synthesis of well-defined bio-
conjugates via site-specific coupling has increased interest in 
tyrosine as a target for protein modification. During the past 
decade, a number of reports have emerged whereby tyrosine 
residues have indeed been targeted. González et al. reported 
the selective mono-iodination of tyrosine residues using io-
dinating reagent IPy2BF4
9 and this has been exploited for the 
introduction of further functionality using Suzuki-Miyaura 
coupling.10 Recently Barbas and co-workers have reported an 
elegant ene-type conjugation of cyclic azadicarboxylate small 
molecules to Tyr residues of model proteins.11 
 Francis and coworkers have reported a number of efficient 
strategies whereby tyrosine residues were targeted via a three-
component Mannich-type reaction, as well as alkylation of the 
residue via the hydroxide group using Trost-allylation condi-
tions,12 and coupling with diazonium reagents. This has reju-
venated the field of diazonium coupling and have described 
several reports on the modification of the tyrosine residues on 
bacteriophage MS2 viral capsids13 and tobacco mosaic virus 
(TMV).14 Wang et al. have since reported a study into the 
 functionalisation of TMV using a combination of diazonium 
coupling at tyrosine and and this has then been adapted to 
modify the tyrosine residues of M13 bacteriophage.15  
Of the three techniques developed by Francis, diazonium-
mediated targeting of tyrosine residues appeared to us to be be 
the most attractive for direct polymer conjugation of 
(poly)peptides. The three-component Mannich-type approach 
is generally a slow reaction, which makes it less attractive for 
the coupling of macromolecules, a process that in itself is 
slower compared to coupling with small molecules. Moreover, 
this generally requires a large excess of coupling reagents,16-18 
which again is less than ideal for polymer conjugation of pro-
teins and peptides. Pd-catalysed O-alkylation by Trost allyla-
tion is an efficient process, although the need for a potentially 
toxic transition metal catalyst (although at very low concentra-
tion) may make this less attractive for the direct preparation of 
protein and peptide derivatives of pharmaceutical interest. 
Conversely, diazonium couplingsare metal-free generally fast 
processes that have the potential for being applied to polymer 
conjugation targeting of medically relevant proteins and pep-
tides. In addition, they have been employed to generate phar-
maceutically relevant therapeutics, including the sulfon-
amidochrysoidine prodrug (Prontosil). 
Despite these promising recent advances, to date, no report 
has described direct polymer conjugation, including PEGyla-
tion, to tyrosine residues of (poly)peptides.  In this current-
work we have developed a novel and potentially general route 
to polymer-peptide biohybrid materials, via preferential target-
ing of peptide tyrosine residues with appropriate diazonium 
salt-terminated polymers with various macromolecular archi-
tectures.  
Results and Discussion 
Design of polymer diazonium coupling agents.  
 Francis and coworkers highlighted the importance of utiliz-
ing highly reactive diazonium salts in order to achieve effi-
cient Tyr targeting.14 The reactivity of diazonium coupling 
agents can be increased by introducing electron-withdrawing 
groups in appropriate positions of their aromatic rings. In this 
regard, Francis et al. reported a decrease in the efficiency of 
diazonium decoration of the exterior protein shell of the to-
bacco mosaic virus (TMV), from >90 to ~30%, by replacing 
the diazonium salt of p-amino-nitrobenzene with the one ob-
tained from p-amino benzamide, i.e. replacement of a NO2 
group to a less electron withdrawing C(O)NH2.  
Diazonium reagents are generally prepared by reacting aro-
matic amines with in situ generated HNO2 or nitrous esters.
19 
In this work a range aniline-terminate-polymers were generat-
ed and converted to the required diazonium derivatives in situ 
during the peptide conjugation experiments. An ester moiety 
was chosen as the para group as, in addition to its electron 
withdrawing properties, it allowed for facile linking of the 
synthetic polymers employed with the aniline diazonium pre-
cursor moieties. In particular, two aniline-terminated 
poly(ethylene glycol)s (3a) and (3b) with FW = 401.5 Da and 
Mn= 2.0 kDa respectively, were prepared (Scheme 1). Briefly, 
Boc-protected 4-aminobenzoic acid (1) was reacted with an 
excess of hexa(ethylene glycol), for (2a), or a monomethoxy 
poly(ethylene glycol) (mPEG, 1.9 kDa) for (2b), in the pres-
ence of EDC and DMAP. Removal of the Boc protecting 
group with trifluoroacetic acid in dichloromethane afforded 
the desired aniline-terminated diazonium precursors (3a) and 
(3b) featuring electron withdrawing ester moieties para- to the 
aromatic amino group. For (3b) overall yields were high (79% 
from mPEG2000 starting material) with extremely high purity 
confirmed by MALDI ToF analysis (see supporting infor-
mation).  
 The range of polymers for use in diazonium conjugation of 
peptides was further expanded by preparing a grafted PEG-
based polymer with different macromolecular architecture, 
p(mPEG MA), bearing the same α-functionality. Conjugating 
polymers with this structure have emerged in recent years as 
key macromolecular intermediates for the preparation of pol-
ymer-(poly)peptide conjugates 20-24 and others.25-28 In this 
study a relatively low molecular weight comb polymer was 
prepared, in order to facilitate the purification and characteri-
zation of the peptide conjugates. 
 
Scheme 1. Synthesis of poly(ethylene glycol)-functional anilines 
as precursors for diazonium-terminated conjugating PEGs 
 
Polymerization29-31  of mPEG(475) MA in the presence of 
Boc-protected-p-aminobenzoic ester initiator (4) and 
Cu(I)Br/pyridinylimine ligand afforded the polymer interme-
diate (5), Mn(NMR) = 8.0 kDa and PDi=1.24. Removal of the 
Boc-protecting group afforded the final aniline-terminated 
poly(mPEG(475) MA) polymer (6), which was used later as a 
diazonium-terminated polymer precursor. 
 
 
Scheme 2. Reagents and conditions: a. Cu(I)Br/N-(ethyl)-2-
pyridylmethanimine, mPEG475MA, toluene, 50 °C; [(4)]:[ 
mPEG475MA]:[Cu]:[ligand] = 1:10:1:3;  b. CF3COOH, dichloro-
methane, 25 °C.   
 
Conjugation to Tyrosine-containing peptides. Coupling 
of diazonium derivatives to (poly)peptides is a technique that 
has been exploited for more than 100 years.32 The high reac-
tivity of these substrates makes them ideal for protein labeling 
although one of the major drawbacks in using this approach 
lies in the very poor selectivity often observed in these conju-
gation reactions.33-35 Diazonium derivatives have been used for 
non-specific targeting of a number of proteins for a range of 
applications spanning from the introduction of haptens onto 
 protein conjugates36 to the supporting of proteins onto PVA 
polymer matrices.37 
Tryptophan has been reported to react efficiently with dia-
zonium salts such as 3-diazonium-1,2,4-triazole (3-DT) at 
very low pH (<3) with reactivity decreasing with an increase 
in pH.38 All of the other amino acid targets, N-nucleophiles 
such as Lysine, (poly)peptide N-termini and Arginine, or C-
nucleophiles Tyrosine and Histidine, and the S-nucleophiles 
free Cysteine, present acid/base moieties which affect their 
reactivity towards diazonium coupling reagents.33 A general 
trend for the N-nucleophiles (Lys, Arg and N-terminal amine) 
is that the lower the pH, the higher proportion of the nucleo-
philic nitrogen centers will be in their protonated form, which 
is non-reactive towards electrophilic reagents.  
Histidine and Tyrosine follow the same trend,37 albeit for 
different reasons. Protonation of the His basic nitrogen re-
moves electronic density from its aromatic ring, which can 
reduce – or even eliminate, depending on the pH - its nucleo-
philic character. Tyrosine residues can, in principle, react with 
nucleophiles both in their neutral Tyr and deprotonated tyro-
sinate forms. The latter, is more reactive than the former and 
an increase in the rate of diazo-coupling with an increase in 
the pH has been observed. For naphthols it has been reported 
that the reactivity of the naphtholate ion, is appoximately 1010 
times higher than that of the undissociated naphthol, implying 
that it always reacts with diazonium salts in its TyrO- form 
unless at pH < 1-2, where the rate coupling reaction is almost 
negligible.  Selective modification of protein Tyr residues so 
far has been restricted either to proteins lacking exposed com-
petitive conjugation sites (i.e. Lys, Cys and His)14 or to less 
reactive diazonium salts bearing a ligand, uridine 2’(3’)-
phosphate, able to direct them in the immediate vicinity of a 
specific Tyr residue in an enzyme binding site (Tyr73 of Ri-
bonuclease A).39 
Herein we reasoned that preferential (or ideally exclusive) 
selectivity in targeting tyrosine residues could have been ob-
tained by utilising appropriate diazonium reagents, by judi-
ciously choosing the experimental conditions at which the 
coupling reactions are performed. The pKa of protonisable 
aminoacids can vary dramatically depending on where these 
fragments are within a (poly)peptide sequence. Remarkable 
differences from expected values are generally observed in 
non-solvent exposed aminoacids in which the presence of hy-
drophobic/hydrophilic local environments in addition to the 
presence of hydrogen bonds can alter remarkably their ac-
id/basic behavior. 
Very broadly speaking, protein N-nucleophiles all feature a 
relatively high pKa in aqueous environments, where the guan-
idine fragment of Arg has pKa ~12, -amino groups of Lys 
residues pKa ~10, N-terminal amino acid residues pKa ~8.40 In 
their protonated form these fragments are not reactive towards 
electrophilic agents (i.e. conjugating polymers). Selective 
PEGylation of (poly)peptide N-terminal aminoacids can be 
achieved by reductive amination with -aldehyde PEGs at pH 
5-6, were a higher proprortion of more basic protein reactive 
sites, i.e. -amino groups of Lys residues, are all in their non 
reactive protonated form.  
The pKa’s of C-nucleophiles can be rather diverse, Tyr typ-
ically having pKa ~10 and His pKa ~6, although for the latter 
an extremely wide range of values, from 2.3 to 9.2, which 
correlate with burial within proteins, have been observed.41 
Due to the high reactivity of tyrosinate/tyrosine residues to-
wards diazonium reagents, the coupling has been reported to 
occur at pH as low as 4.37 In the same study the authors report-
ed that over the 4.0-9.0 interval of pH investigated, Tyr ana-
logues had higher reactivity than the corresponding His de-
rivatives. 
In this present work we aimed at reducing the pH at which 
the conjugation reaction was conducted to a point in which all 
nitrogen-containing amino acid would be in their protonated 
and non-reactive form, whilst utilizing reactive diazonium 
coupling agents till able to react with Tyr residues under these 
conditions. Tracey and Shuker have shown that the even at 
higher pH of 8.8, EWG-activated diazonium salts have the 
tendency to react with Tyr and His, even in the presence of 
unprotected Trp, Lys and terminal amino group.42 
For the first conjugation experiment a model peptide, [D-
ala2]-leucine enkephalin, an opioid pentapeptide containing a 
single tyrosine residue, was chosen (Scheme 3). In addition to 
the substituted phenol, Tyr1 presents an N-terminal amino 
group that could represent a competitive attachment site for 
polymer conjugation. Hexa(ethylene glycol) precursor (3a) 
was used as the conjugating agent, due to his intrinsically 
monodisperse nature and small size, which facilitated the 
study of the coupling reaction and the characterization of the 
final adduct(s). The conjugation reaction was carried out at pH 
4.5, where all the amino groups were expected to be mainly in 
their protonated and non-reactive form. The process was 
monitored by 1H NMR and was found to be extremely neat, 
with rapid and quantitative synthesis of diazonium derivatives 
from the parent anilines (see supporting information). The 
required diazonium salts was generated in situ by sequential 
addition of trifluoroacetic acid and NaNO2, at 0 °C. After 30 
min sulfamic acid was added, so as to destroy excess nitrous 
acid generated in the previous step. The pH was adjusted to 
4.5 with 500 mM acetate buffer and [D-ala2]-leucine enkepha-
lin was finally added. The reaction was performed at 4 °C for 
24 h, during which the colour of the reaction solution gradual-
ly turned from colorless to orange due to formation of the azo-
benzene linker. After quenching of the excess diazonium cou-
pling agent with p-cresol and purification by SEC chromatog-
raphy, MALDI-ToF-MS analysis revealed the presence of a 
single product with the expected m/z = 982 Da [M+H]+ for the 
monoadduct (3a)-enkeph (see supporting information). It is 
important to note that (3a)-enkeph monoadduct was only 
product observed, even though a 10:1 excess of diazonium 
conjugating agent was employed in the coupling reaction. 
 
Scheme 3. Conjugation of diazo-functional model-PEG (3a) to 
Tyr1 residue of [D-ala2]-leucine enkephalin. 
 
Following this successful modification of [D-ala2]-leucine 
enkephalin, the versatility of the conjugation strategy was 
tested with a more complex peptide, Salmon Calcitonin (sCT). 
sCT is a 32-aminoacid hormone currently prescribed for the 
treatment of bone-related disorders including osteoporosis, 
Paget’s disease and hypercalcemia. sCT’s ipocalcemic proper-
 tities have been ascribed to a number of concurrent phenome-
na, including its ability to inhibit the activity of osteoclasts in 
bones, and to promote Ca2+ renal excretion.43 Most important-
ly for the scope of this study, sCT is a very well characterised 
peptide which presents only one Tyrosine residue (Tyr22) for 
polymer conjugation, in addition to a number of other poten-
tial conjugating sites, Cys1 (N-terminal amine), Lys11 and 
Lys18, His17, and Arg24, which made sCT an ideal substrate 
for testing the selectivity of the diazonium conjugation pro-
cess. Moreover, Tyr22 is included in a short portion of the 
primary structure of sCT - from Leu19 to Tyr22 - that can be 
modified, or even completely removed, with no loss of bioac-
tivity.44 This made Tyr22 an ideal targeting site, as its modifi-
cation was expected to have minimal impact on the bioactivity 
of sCT.  
Scheme 4. Conjugation of mPEG diazonium precursors (3a) 
and (3b) to salmon calcitonin (sCT). 
 
Initial investigations were again conducted using the 
hexa(ethylene glycol) precursor (3a) under conditions analo-
gous to those previously optimized for [D-ala2]-leucine 
enkephalin. Upon addition of sCT, no immediate colour 
change was observed but over a period of time, the solution 
became orange, due to the formation of the azo-linker. Sam-
ples were taken periodically and analysed by MALDI-ToF-
MS. Analysis of the reaction mixture taken after 8 h confirmed 
the presence of unreacted sCT, along with a single peak corre-
sponding to the mass of (3a)-sCT conjugate (Figure 1). It 
should be noted that MALDI-ToF-MS spectrometry is re-
markably more sensitive to unmodified sCT than to (3a)-sCT, 
with the latter found to be the major product at the end of the 
diazonium coupling reaction. Neither for the synthesis of (3a)-
enkeph not for (3a)-sCT, peak corresponding to the loss of 17 
mass units from the conjugates, commonly observed in diazo-
nium coupling with proteins and peptides,14 was observed. 
Figure 1. MALDI-ToF-MS spectrum of the diazonium-
coupling reaction of sCT with (3a) at pH 4.5, at [sCT]0:([(3a)]0 
=1:20. 
Although the exact nature of such elimination product has 
never been established, one explanation for this could be a 
formal elimination of ammonia, possibly via reaction of the 
diazonium derivative with either the N-terminal amine or a 
Lys residue to generate a monoalkykl-triazene, followed by its 
-elimination, a common decomposition route for these inter-
mediates45, 46 (although other degradation processes are also 
possible).47 
 
The influence of the pH on the selectivity of the coupling 
process was then investigated by performing the conjugation 
reaction at pH 7.0 (500 mM). Upon incubation of sCT, an 
immediate colour change was observed with the solution turn-
ing dark purple. RP-HPLC analysis indicated that sCT had 
been immediately consumed and MALDI-ToF-MS analysis of 
the reaction solution showed a mixture of products, ranging 
from a small peak corresponding to native sCT to the polypep-
tide conjugated to as many as five molecules of hexa(ethylene 
glycol) diazonium (3a)  (Figure 2). The presence of up to five 
molecules of conjugating molecules per sCT is may be 
ascribed to conjugation to Tyr22, His17, the N-terminal amine, 
Lys11 and Lys18, whilst the pKa of the Arginine (Arg24) may 
be too high to ensure efficient conjugation of this residue at 
pH 7.0. 
 
Figure 2. Hyperfine MALDI-ToF-MS spectrum of the diazonium-
coupling reaction of sCT with hexa(ethylene glycol) diazonium 
(3a) performed at pH 7.0, at ([(3a)]0:[sCT]0 = 10:1. 
The coupling reaction conducted at intermediate pH values, 
namely 5.4 and 6.2, led to multiple conjugation similar to that 
observed at pH 7.0, although the observed rate of conjugation 
was significantly slower (see supporting information). 
Conjugation with mPEG2000 (3b) at pH 4.5 was performed at 
2.5, 10 and 20 (3b):sCT molar ratios in order to optimise the 
rate and efficiency of the conjugation reaction. The reaction 
was monitored by RP-HPLCequipped with a C18 column. 
Conversion was found to be 21, 54, and 78%, respectively, 
after 56 h.. 
Pure (3b)-sCT was isolated, with relatively low purification 
yield (24%), after ion exchange –FPLC. MALDI-ToF-MS 
analysis (Figure 3) showed a single distribution of peaks with 
the observed mass in the range expected for (3b)-sCT. No 
conjugates with higher molecular mass were detected, neither 
by RP-HPLC nor MALDI-ToF-MS, suggesting again that 
under the conditions employed a 1:1 polymer:sCT was ob-
tained. 
 Finally, the same coupling reaction was performed utilizing 
poly(mPEG(475) methacrylate) (6) as the diazonium precur-
sor. The coupling process proved to be as efficient as the ones 
previously performed with the structurally simpler linear pol-
ymers (3a) and (3b), reaching 90% after 72 h at 4°C. Again, 
the conjugate was purified by ion-exchange chromatography 
(FPLC) affording pure conjugate. Biohybrid materials consist-
ing of protein or peptide conjugates with comb mPEG 
(meth)acrylates are extremely difficult to characterize by 
MALDI-ToF mass spectrometry48 with the only known exam-
ple reported to date being restricted to conjugates with low 
Mn.
49 The conjugate sCT-(6) was characterized by cleavage of 
the diazo linker followed byanalysis of the resulting modified 
peptide and its tryptic digests (vide infra). All polymer conju-
gations were repeated several times (3 to 5 depending on the 
conjugate) and results were found to be reproducible.  
 
Figure 3. (top) MALDI-ToF-MS analysis of purified sCT-(3b) 
(PEG2000). (bottom) Detail of sodiated and protonated (3b)-sCT. 
(3b)-sCT. A more detailed account is reported in the supporting 
information section. 
 
Characterization of sCT-polymer conjugates: attach-
ment site. 
Following observations that under specific conditions, sCT-
polymer monoconjugates could be synthesized, it was neces-
sary to confirm the conjugation site. An immediately evident 
feature of all the conjugation reactions is the change of colour 
from colourless to orange, indicative of the formation of diazo 
adducts. In addition, the colour seemed to assume a more in-
tense orange coloration with increasing pH. UV-vis analysis of 
isolated (3b)-sCT showed a maximum at λ = 471 nm, and up-
on lowering gradually the pH to 5.0, a disappearance of this 
was observed, with the formation of a band at λ = 372 nm 
(Figure 3). For comparison purposes, the diazonium salt of 
(3b) was conjugated with water-soluble model histidine (8) 
and tyrosine (9) mimics. UV-vis spectra of the isolated conju-
gates (3b)-(8) prepared from a His mimic showed very little, if 
any, dependence on the pH. Conversely, analysis of (3b)-(9) 
bearing a Tyr mimic changed markedly with the pH, with a 
band at approximately 500 nm with intensity that increased 
with the pH, a behavior which parallel that observed for the 
calcitonin conjugate (3b)-sCT. This is in agreement with liter-
ature data for other diaza-Tyr conjugates, in which the appear-
ance of a band at approximately 500 nm was ascribed to a 
chromophore formed by deprotonation of a diaza-phenolic 
moiety.39 Further titration studies allowed to estimate a 
pKa~11 for both the model diaza-Tyr conjugate (3b)-(9) and 
(3b)-sCT, again suggesting a strong involvement of Tyr22 in 
the diazonium polymer conjugation reaction. 
 
Figure 4. UV-Vis spectra of (3b)-sCT and purified conjugates of 
(3b) with histidine (8), and tyrosine (9) mimics, at various pH. 
Further investigations involved the isotopic labeling of the 
peptide conjugates using Na15NO2 for the preparation of dia-
zonium salts used for the coupling reactions. This allowed for 
the investigation of the peptides amino acid attachment site, by 
NMR, and also providid a means to discriminate the nitrogen 
atom introduced in the peptides from the nitrogen’s already 
present, facilitating the characterization of the conjugates pep-
tides by mass spectrometry.  
Conjugation reaction of (3a) to [D-ala2]-leucine enkephalin, 
and aniline-functional linear (3b) and comb (6) polymers to 
sCT was repeated as described previously, this time using 
Na15NO2. TOCSY NMR of (3a)-[D-ala
2]-leucine enkephalin 
confirmed the conjugation of (3a) to the model pentapeptide. 
Although the presence of conformational isomers makes the 
analysis of the conjugate rather complicated, spin systems 
corresponding to a 1,3,4-tri-substituted benzene ring further 
 provide strong evidence of conjugation to Tyr1 (see support-
ing information).  
An additional potential advantage offered by peptide conju-
gates bearing a diazo linker is the possibility to selective 
cleavage in the presence of specific external reducing stimuli, 
i.e. colon azoreductase enzymes. Several currently prescribed 
therapeutics, i.e. Ipsalazide, Balsalazide and Sulfasalazine, are 
administered as prodrugs containing diazo linkers that can be 
cleaved by colon azoreductases releasing the required active 
drugs.50, 51 Several drug delivery systems based on polymer 
containing diazo linkers have also been extensively investigat-
ed.51-53 Reversible PEGylation of peptides with and colon re-
lease are beyond the scope of the present work.  
The polymers were cleaved from the conjugated peptides 
using sodium dithionite. The reaction was optimized and in-
vestigated using a model tyrosine conjugated prepared by re-
acting the diazonium derivative obtained from mPEG aniline 
(3b) and p-cresol. This was then used in conjugation reactions 
as a means to quench the excess of diazonium polymers. Con-
jugates with p-cresol were therefore produced at the end of 
every conjugation run, and appeared to be ideal simple sub-
strates for the optimization of the reductive cleavage of diaza 
linkages. Upon addition of 1 eq. of sodium dithionite reducing 
agent an immediate loss of the characteristic orange colour of 
the model conjugated was observed, indicating rapid and 
quantitative cleavage of the azobenzene-linker, yielding the 
parent aniline functional polymers and 2-amino-4-methyl phe-
nol, as confirmed by 1H NMR, UV-Vis and MALDI-ToF-MS 
analysis (see supporting information). 
 
Scheme 5. 15N isotopic labelling of the azobenzene linker in the 
diazonium coupling of aniline mPEG (3b) to sCT, followed by 
release of 15NH2-sCT by reductive cleavage with Na2S2O4. 
 The experiment was then repeated with 15N labeled (3b)-
sCT and (6)-sCT which resulted in the release of sCT with an 
additional 15NH2 group (Scheme 5 for (3b)-sCT). 
 
 
Figure 5. MALDI-TOF spectrum of sCT-15NH2 adduct ob-
tained by cleavage of the (6)-sCT azo-linker using sodium 
dithionite. 
Again, upon addition of sodium dithionite to a solution of 
all sCT conjugates at pH 7.2, an immediate loss of the charac-
teristic orange colour of the linker was observed and the re-
duction confirmed by UV-Vis spectroscopy. 
MALDI-ToF-MS analysis of the cleaved conjugates (Figure 
5 for (6)-sCT) confirmed the presence of the amino-modified 
sCT, with the expected mass gain of 16.0 Da observed due to 
introduction of a -15NH2 group to the polypeptide. Small sig-
nals corresponding to unmodified sCT and traces higher mass 
species were also observed, which may be derived from higher 
conjugated species. Qualitative analysis of MALDI-ToF-MS 
spectra showed that smaller amounts of these minor impurities 
were present when poly(mPEG(475) MA) (6) was employed, 
suggesting that its branched structure may provide better pro-
tection towards further polymer conjugation.  
In order to determine the modification site of the amino-
modified polypeptides sCT-15NH2 obtained by reductive 
cleavage of sCT-polymer conjugates were subjected to trypsin 
digestion, which cleaved them at the C-terminus of their Lys 
and Arg residues. Under these conditions unmodified sCT 
yields four fragments, Cys1-Lys11, Leu12-Lys18, Leu19-
Arg24, and Thr25-Pro(NH2)32. This approach to determine 
the attachment site in sCT-polymer conjugates was conducted 
by analogy to that previously described by us49 and Lee et al.54 
His17 and Tyr22 residues reside on separate fragments, 
Leu12-Lys18 and Leu19-Arg24 respectively, and therefore the 
selectivity of the conjugation process could be determined by 
MALDI-ToF-MS analysis of the digest fragments. For both 
15N (3b)-sCT and (6)-sCT analysis of the region correspond-
ing to the Leu19-Arg24 tyrosine-containing fragment revealed 
a distribution corresponding to a 15NH2 labeled fragment (ad-
dition of 16 Da) as well as the analogous residue from the 
digestion of the traces of unconjugated sCT present as an im-
purity in the isolated (6)-sCT biohybrid material, and some 
secondary distributions (Figure 6). 
 
Figure 6. Trypsin digestion of (6)-sCT conjugate: MALDI ToF 
MS analysis of Leu12-Lys18 and Leu19-Arg24. 
All of the other trypsin digest fragments were identical to 
those of native sCT, which is consistent of little, if any, conju-
 gation of the diazonium polymer at any other residues but 
Tyr22.  
 
In vitro and in vivo preliminary studies on the bioactivity 
of sCT-polymer conjugates. In order to assess the biological 
activity of the conjugates prepared in this study, in vitro tests 
were carried out by monitoring the ability of the (3b)-sCT 
conjugate to recognize and activate the calcitonin receptor in 
T47D human breast cancer cells. 
 
Figure 7. ELISA measurement of the increase of intracellular 
cAMP induced in T47D human breast cancer cells bearing sCT 
receptors by (3b)-sCT and native sCT. 
In vitro results revealed that (3b)-sCT was able to signifi-
cantly elevate intracellular cAMP levels (Figure 7) with no 
loss in bioactivity compared to native sCT. In these experi-
ments two negative controls, PBS alone and and polymer (3b) 
in PBS were employed. Both negative controls showed no 
cAMP was produced. A positive control; forskolin was also 
included to ensure that the cell model was working correctly.  
Following the very promising in vitro behavior of this con-
jugate, in vivo tests aimed at investigating the ability of (3b)-
sCT to lower [Ca2+] plasma levels in mammals were conduct-
ed using male Wistar rats. Blood samples were taken periodi-
cally up to 240 minutes after injections into the tail vein and 
the plasma total calcium analysed. The (3b)-sCT conjugate 
was shown to have a comparable ability in lowering plasma 
calcium compared to unmodified sCT (Figure 8). Negative 
control data using i.v. injection of PBS were without effect on 
plasma calcium levels.22  Homeostatic events mean that plas-
ma calcium levels do not move from 2.5 mM in untreated 
conditions. 
 
Figure 8. Plasma total calcium profiles of male Wistar rats follow-
ing intravenous injections of sCT (blue triangles) and (3b)-sCT 
conjugate (green circles). 
In summary, this work describes novel general approach to 
direct polymer conjugation to peptides, based on diazonium-
terminated materials with various macromolecular architec-
ture. A short oligoethylene glycol, a well-defined linear PEG 
and poly(mPEG(475) methacrylate) prepared by ATRP were 
synthesized and employed for the targetting of Tyr residues of 
[D-ala2]-leucine enkephalinamide and salmon calcitonin mod-
el peptides. Experimental conditions, especially in terms of the 
pH used for the peptide conjugation reactions, were optimized 
for the specific targeting of tyrosine residues. UV-vis and 
NMR experiments, in conjunction with mass spectrometry 
analysis of the fragments obtained from trypsin digestion of 
reduced polymer-peptide conjugates indicated good selectivity 
for Tyr conjugation. Preliminary in vitro experiments aiming 
at monitoring the increase of intracellular cAMP induced in 
T47D human breast cancer cells bearing sCT receptors by 
(3b)-sCT revealed a virtually identical potency for the diazo 
protein-peptide conjugate compared to native sCT. This 
PEGylation approach is reversible and parent aniline polymers 
can be recovered from their peptide conjugates in the presence 
of appropriate reducing agents, including sodium dithionite, 
and, potentially, azoreductase enzymes like those found in the 
gastrointestinal tract of mammals.55,56, 57 which may open the 
way for the use of our approach for the development of colon 
specific drug delivery systems. In vivo preliminary experi-
ments revealed that our diazo sCT-PEG2000 conjugate dis-
played a comparable ability in lowering the plasma [Ca2+] of 
male Wistar rats.  
The approach for polymer-peptide conjugation presented in 
this work could complement well the set of polymer conjuga-
tion techniques – i.e. N-terminal amine conjugation with alde-
hyde-functional polymers - that already allow to preferentially 
(or sometimes exclusively) target specific peptide amino acids 
in the presence of other possible peptide conjugation sites. 
Direct polymer conjugation to tyrosine residues appears to be 
a rather versatile approach and could potentially be applied to 
conjugates which include a plethora of different polymeric 
materials other than PEG or PEG-based polymers. In addition, 
this strategy could be expanded to a number of other biologi-
cally relevant peptides (and possibly proteins), as long as the 
conjugation conditions are optimized to take into account the 
specific characteristics (i.e. exposition and pKa of relevant 
amino acid residues) of the conjugated peptide. This work 
showed that for the specific case of sCT Tyr22 conjugation 
with linear PEG2000 occurred with no loss of bioactivity in 
vitro, as measured by the increase of intracellular cAMP in-
duced in T47D human breast cancer cells bearing sCT recep-
tors. Preliminary experiments in vivo showed that the same 
conjugates had ability to lower plasma total [Ca++] in Wistar 
Rats comparable to that of sCT, further confirming that poly-
mer conjugation did not interfere with the bioactivity of sCT. 
Tyr22 is included in a portion of the sCT peptide sequence 
that can be modified or even removed with no loss of bioactiv-
ity. This in itself highlights the importance of having an ample 
toolkit of conjugation techniques that allow site-specific con-
jugation at sequence domains that are not involved in the ac-
tive sites of proteins and peptides. The present study aimed at 
complementing the existing polymer conjugation techniques 
with what to the best of our knowledge is the first example of 
site-specific direct polymer conjugation at Tyr residues.  
  
Supporting Information. Experimental section, including syn-
thetic procedures, characterization of polymers and all intermedi-
ates, bioconjugation experiments, in vitro and in vivo test proce-
dures.  This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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